Z.A. GONCHAROVA, Yu.Yu. POGREBNOVA, N.M. YAROCH

Rostov-on-Don State Medical University, 29 Nakhichevanskiy pereulok, Rostov-on-Don, Russian Federation, 344022

 Goncharova Z.A. ― D. Sc. (medicine), Professor of the Department of Nervous Diseases and Neurosurgery, e-mail: centrms@mail.ru, ORCID ID: 0000-0001-7093-9548

Pogrebnova Yu.Yu. ― postgraduate student of the Department of Nervous Diseases and Neurosurgery, e-mail: 3ae40n0k@mail.ru, ORCID ID: 0000-0002-7112-767X

Yaroch N.M. ― neurologist of the Neurology Center, e-mail: yarosh-nats@mail.ru, ORCID ID: 0000-0002-4616-0750

 Objective ― to characterize the modern view on the classification of idiopathic inflammatory demyelinating diseases (IIDD) from the viewpoint of application in neurologist’s everyday practice.

Material and methods. A review of literature was carried out; own data were obtained by statistical observation with the maximum coverage of patients in Rostov-on-Don Center for Multiple Sclerosis on a control day (1 January 2018).

Results. The register of Rostov-on-Don Center for Multiple Sclerosis lists 721 people with IIDD. Of these, with a reliable diagnosis of MS according to McDonald criteria (2010) ― 622 people, i.e. 86.3% of the total number of IIDD. Men accounted for 26.4% (164 people), women ― 73.6% (458 people); 444 people (58.5%) have recurring-remitting MS; 132 patients have second-progressive disease (17.39%), 46 people (6.1%) have primary-progressive disease; 66 (9.15%) have CIS, 1 person (0.14%) has pseudotumorous MS. There are patients with rarer forms of demyelinating diseases, such as RIS ― 4 people (0.55%), OREM ― 19 people (2.6%), ONM ― 3 (0.4%), idiopathic myelitis ― 3 (0.4%), chronic recurrent optic neuritis ― 3 (0.4%).

Conclusion. Based on the carried out analysis, one can conclude that new methods appear which allow verifying rarer forms of idiopathic inflammatory demyelinating diseases, the criteria are clarified for diagnosing the most common forms such as multiple sclerosis, CIS, and Davic’s disease. This allows more efficient differentiating the IIDD diseases. According to the literature data, in 2004 RS accounted for more than 90% of IIDD; to date, according to our data, that is 86.3%. This indicates the need for a more attention to the rare IIDD forms and the fastest possible differential diagnosis with MS. To do this, it is necessary to define clear differential diagnostic criteria for each IIDD disease, which will allow to choose the optimal tactics of patient management in due time.

Key words: idiopathic inflammatory demyelinating diseases, classification, multiple sclerosis, acute multiple encephalomyelitis, Davic’s disease.

(For citation: Goncharova Z.A., Pogrebnova Yu.Yu., Yaroch N.M. Idiopathic inflammatory demyelinating diseases of the Central nervous system: modern view on classification, experience of making a register. Practical Medicine. 2018)

REFERENCES:

1. Zhuravlev M.N., Sivertseva S.A., Molokova M.Y., et al. Myelitis optica or Devik’s disease: pathogenesis, clinic, diagnosis and treatment experience using betaferon and mitoxantrone. Zhurnal Nevrologiii Psikhiatrii imeni S.S. Korsakova, 2007, no. 4, pp. 106-112.
2. Warabi Y., Matsumoto Y., Hayashi H. Interferon beta-1 b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. Neurol Sci, 2007, no. 252, pp. 257–261.
3. Love S. Demyelinating diseases. Clin. Pathol, 2006, no. 59 (11), pp. 1151–1159.
4. Ashraf М. Childhood central nervous system acquired demyelinating disorders: incidence, clinical features, MRI characteristics and prognostic features. DSc dissertation. Birmingham, 2013, 318 p.
5. Fontaine B. Borderline forms of multiple sclerosis. Neurol. (Paris), 2001, no. 157 (8-9, 2), pp. 929–934.
6. Wingerchuk D.M., Lucchinetti C.F. Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitisoptica, and multiple sclerosis. Opin. Neurol, 2007, no. 20 (3), pp. 343–350.
7. Poser C.M., Brinar V.V. Disseminated encephalomyelitis and multiple sclerosis: two different diseases — a critical review. ActaNeurol Scand, 2007, no. 116 (4), pp. 201-206.
8. Weinshenker B., Miller D. Multiple sclerosis: one disease or many? In Thompson AB, Siva A, Kesselring J. Frontiers in Multiple Sclerosis (2nd ed.). London: Taylor & Francis Group, 1998, pp. 37–46
9. Hrtung H.P., Grossman R.I. ADEM: distinct disease or part of the MS spectrum?  Neurology, 2001, no. 56 (10), pp. 1257–1260.
10. Fernández O., Fernández V.E., Guerrero M. Demyelinating diseases of the central nervous system. Medicine, 2015, no. 11 (77), pp. 4601–4609.
11. Stock B.H., Levin O.S., Borisov B.A., et al. Demyelinating diseases of the Central nervous system. Guide to the formulation of a clinical diagnosis of diseases of the nervous system, 2006, pp. 88-99.
12. Totolyan N.A. Diagnosis and differential diagnosis of idiopathic inflammatory demyelinating diseases of the central nervous system, dissertation for the degree of Doctor of Medical Sciences, St. Petersburg, 2004, 132 p.
13. Polman C.H., Reingold S.C., Banwell B., et al. Diagnosticcriteriaformultiplesclerosis: 2010 revisions to the McDonald criteria. Neurol, 2011. vol. 69, pp. 292–302.
14. Wingerchuk D.M., Lennon V.A., Pittock S.J., et al. Revised diagnostic criteria for neuromyelitisoptica. Neurology, 2006, vol. 66, pp. 1485–1489.
15. Wingerchuk D.М., Lennon V.A., Lucchinetti C.F., et al. The spectrum of neuromyelitisoptica. Neurol. 2007, vol. 6, P. 805–815.
16. Wingerchuk D.M., Banwell B., Bennett J.L., et al. International consensus diagnostic criteria for neuromyelitisoptica spectrum disorders. Neurology, 2015, no. 85, pp. 177–189.
17. Wingerchuk D.W., Weinshenker B.G. Unusual presentations and variants of idiopathic central nervous system demyelinating diseases In: Raine C, McFarland HF, Hohlfeld R, editors. Multiple sclerosis: A comprehensive text New York: Saunders/Elsevier, 2008, pp. 24–42.
18. Miller D.H., Weinshenker B.G., Filippi M., et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. MultScler, 2008, no. 14, pp. 1157–1174.
19. Polman C.H., Reingold S.C., Banwell B., et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011, no. 69, pp. 292–302.
20. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol, 2003, no. 2, pp. 117–127.
21. Regina M.P., Claudia C.F.V., Adriana C. Central Nervous System Idiopathic Inflammatory Demyelinating Disordersin South Americans: A Descriptive, Multicenter, Cross-Sectional Study. pone, 2015, no. 10(7).
22. Cañellas A.R., Gols A.R., Izquierdo J.R, et al. Idiopathic inflammatory-demyelinating diseases of the central nervous system. Neuroradiology, 2007; no. 49 (5), pp. 393-409.
23. Polman C.H., Reingold S.C., Banwell B., et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol, 2011, no. 69(2), pp. 292–302.
24. De Seze J., Debouverie M., Zephir H., et al. Acute fulminant demyelinating disease: a descriptive study of 60 patients. Arch Neurol, 2007, no. 64(10), 1426 p.
25. Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology, 2003; no. 60(4), 730 p.
26. Shams P., Plant G. Optic neuritis: a review. International MS journal/MS Forum, 2009, 82 p.
27. Kim S.-M., Waters P., Woodhall M., et al. Characterization of the spectrum of Korean inflammatory demyelinating diseases according to the diagnostic criteria and AQP4-Ab status. Neurology, 2014, no. 14, pp. 93-98.
28. Oliver T., Chiara C., Yong G., et al. Clinical, radiological and morphological variants of idiopathic inflammatory demyelinating disease of the central neurological system in the elderly. Multiple Sclerosis Journal, 2017, no. 23 (9), pp. 1204-1213.
29. Bruchet B., Neuropsychiatric Symptoms of Inflammatory Demyelinating Diseases. Springer, London, 2015, pp. 4-6.
30. Limoli C.L., Giedzinski E., Baure J., et al. Using superoxide dismutase/catalase mimetics to manipulate the redox environment of neural precursor cells. Prot. Dosimetry. 2006, no. 122, no. 228–236.
31. Bardychev M.S., Kurpesheva A.K., Pasov V.V. et al. Radiation damage in the Hodgkin’s disease treatment. Materials of 6th Russian oncology conference, Moscow, 2002.
32. Goncharova Z.A., Yaroch N.M., Pogrebnova Y.Y., et al. Difficulties of diagnostics of post radial myelopathy. Siberian Medical Review, 2017, no. 1, pp. 74-77.
33. Goncharova Z.A., Yaroch N.M., Pogrebnova Y.Y. Late post-radial myopathy: the mechanisms of demyelination, the complexity of diagnosis. Practical medicine, 2017, no. 1 (102), pp.173-176.